Patents by Inventor Claudio Soto

Claudio Soto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190353669
    Abstract: Methods and kits for evaluating a subject for a brain injury are described. The method may include providing at least one biological sample from the subject having or suspected of having the brain injury. The method may include conducting one or more amplification reactions, including contacting a portion of the biological sample with a monomeric, folded tau protein to form an incubation mixture. Each amplification reaction may include determining a presence or amount of the misfolded tau protein in the biological sample according to the amplified portion of the misfolded tau protein. Methods for evaluating the risk of neurodegenerative disease or disorder in a subject having suffered from brain injury are also described.
    Type: Application
    Filed: May 16, 2019
    Publication date: November 21, 2019
    Inventors: Russell M. Lebovitz, Benedikt K. Vollrath, Luis Concha, Claudio Soto-Jara
  • Publication number: 20190137515
    Abstract: Described are methods for estimating misfolded protein concentration in fluids and tissues by quantitative PMCA.
    Type: Application
    Filed: December 27, 2018
    Publication date: May 9, 2019
    Inventors: Claudio Soto, Baian Chen, Rodrigo Morales
  • Patent number: 10215763
    Abstract: The present embodiments disclose methods for estimating PrPSc concentration in fluids and tissues by quantitative PMCA.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: February 26, 2019
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Claudio Soto, Baian Chen, Rodrigo Morales
  • Publication number: 20180335438
    Abstract: Methods and kits are provided for amplifying and detecting misfolded tau protein from samples, for example, from patients having tauopathies such as Alzheimer's Disease, Progressive Supranuclear Palsy, and the like.
    Type: Application
    Filed: May 16, 2018
    Publication date: November 22, 2018
    Applicants: Amprion, Inc., BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Claudio Soto-Jara, Russell M. Lebovitz, Benedikt K. Vollrath, Mohammad Shahnawaz, Nicolas Mendez Dinamarca
  • Publication number: 20180196069
    Abstract: Methods and kits are provided for amplifying and detecting misfolded proteins from samples, for example, from patients having Alzheimer's Disease, Parkinson's Disease, and the like. For example, a method for determining a presence of soluble, misfolded protein in a sample may include contacting the sample with a monomeric, folded protein to form an incubation mixture; conducting an incubation cycle two or more times effective to form an amplified portion of misfolded protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded protein; physically disrupting the incubation mixture effective to break up at least a portion of any protein aggregate present; and determining the presence of the soluble, misfolded protein in the sample by detecting at least a portion of the soluble, misfolded protein. The monomeric, folded protein and the soluble, misfolded protein may exclude prion protein (PrP) and isoforms thereof.
    Type: Application
    Filed: March 8, 2018
    Publication date: July 12, 2018
    Applicants: Board of Regents of the University of Texas System, Amprion, Inc.
    Inventors: Claudio Soto-Jara, Russell M. Lebovitz, Benedikt K. Vollrath, Mohammad Shahnawaz
  • Publication number: 20180196068
    Abstract: Methods and kits are provided for amplifying and detecting A? proteins from samples, for example, from patients having Alzheimer's Disease. For example, a method for determining a presence of a soluble, misfolded A? protein may include contacting the sample with a monomeric, folded A? protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded A? protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded A? protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded A? aggregate present; and determining the presence of the soluble, misfolded A? protein in the sample by detecting at least a portion of the amplified portion of misfolded A? protein.
    Type: Application
    Filed: March 5, 2018
    Publication date: July 12, 2018
    Inventors: Claudio Soto-Jara, Russell M. Lebovitz, Benedikt K. Vollrath, Mohammad Shahnawaz
  • Patent number: 9910049
    Abstract: Methods and kits are provided for amplifying and detecting A? proteins from samples, for example, from patients having Alzheimer's Disease. For example, a method for determining a presence of a soluble, misfolded A? protein may include contacting the sample with a monomeric, folded A? protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded A? protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded A? protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded A? aggregate present; and determining the presence of the soluble, misfolded A? protein in the sample by detecting at least a portion of the amplified portion of misfolded A? protein.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: March 6, 2018
    Assignees: AMPRION, INC., THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Claudio Soto Jara, Mohammad Shahnawaz, Russell M. Lebovitz, Benedikt K. Vollrath
  • Publication number: 20160077111
    Abstract: Methods and kits are provided for amplifying and detecting ?S proteins from samples, for example, from patients having Parkinson's Disease. For example, a method for determining a presence of a soluble, misfolded ?S protein may include: contacting the sample with a monomeric, folded ?S protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded ?S protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded ?S protein in the presence of the soluble, misfolded ?S protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded ?S aggregate present; and determining the presence of the soluble, misfolded ?S protein in the sample by detecting at least a portion of the soluble, misfolded ?S protein.
    Type: Application
    Filed: September 11, 2015
    Publication date: March 17, 2016
    Inventors: Claudio Soto Jara, Mohammad Shahnawaz, Russell M. Lebovitz, Benedikt K. Vollrath
  • Publication number: 20160077112
    Abstract: Methods and kits are provided for amplifying and detecting misfolded proteins from samples, for example, from patients having Alzheimer's Disease, Parkinson's Disease, and the like. For example, a method for determining a presence of soluble, misfolded protein in a sample may include contacting the sample with a monomeric, folded protein to form an incubation mixture; conducting an incubation cycle two or more times effective to form an amplified portion of misfolded protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded protein; physically disrupting the incubation mixture effective to break up at least a portion of any protein aggregate present; and determining the presence of the soluble, misfolded protein in the sample by detecting at least a portion of the soluble, misfolded protein. The monomeric, folded protein and the soluble, misfolded protein may exclude prion protein (PrP) and isoforms thereof.
    Type: Application
    Filed: September 11, 2015
    Publication date: March 17, 2016
    Inventors: Claudio Soto Jara, Mohammad Shahnawaz, Russell M. Lebovitz, Benedikt K. Vollrath
  • Publication number: 20160077110
    Abstract: Methods and kits are provided for amplifying and detecting A? proteins from samples, for example, from patients having Alzheimer's Disease. For example, a method for determining a presence of a soluble, misfolded A? protein may include contacting the sample with a monomeric, folded A? protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded A? protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded A? protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded A? aggregate present; and determining the presence of the soluble, misfolded A? protein in the sample by detecting at least a portion of the amplified portion of misfolded A? protein.
    Type: Application
    Filed: September 11, 2015
    Publication date: March 17, 2016
    Inventors: Claudio Soto Jara, Mohammad Shahnawaz, Russell M. Lebovitz, Benedikt K. Vollrath
  • Publication number: 20110311997
    Abstract: The present embodiments disclose methods for estimating PrPSc concentration in fluids and tissues by quantitative PMCA.
    Type: Application
    Filed: May 18, 2011
    Publication date: December 22, 2011
    Inventors: Claudio Soto, Baian Chen, Rodrigo Morales
  • Publication number: 20110086057
    Abstract: The present invention discloses peptides isolated from the extracellular domain of OX40 Ligand (OX40L) capable of binding OX40 Receptor (OX40R) and inhibiting OX40R-OX40L interaction. Such peptides, fusion proteins comprising them, as well as peptides and other molecules designed on their sequences, can be used as OX40R binding agents competing with natural OX40L for blocking OX40R-mediated cell signaling in the prophylaxis and/or treatment of diseases related to activated T cells.
    Type: Application
    Filed: November 23, 2010
    Publication date: April 14, 2011
    Applicant: MERCK SERONO SA
    Inventors: Claudio Soto-Jara, Claudia Pena-Rossi
  • Patent number: 7858765
    Abstract: The present invention discloses peptides isolated from the extracellular domain of OX40 Ligand (OX40L) capable of binding OX40 Receptor (OX40R) and inhibiting OX40R-OX40L interaction. Such peptides, fusion proteins comprising them, as well as peptides and other molecules designed on their sequences, can be used as OX40R binding agents competing with natural OX40L for blocking OX40R-mediated cell signaling in the prophylaxis and/or treatment of diseases related to activated T cells.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: December 28, 2010
    Assignee: Merck Serono SA
    Inventors: Claudio Soto-Jara, Claudia Pena-Rossi
  • Patent number: 7758852
    Abstract: The present invention discloses peptides isolated from the extracellular domain of OX40 Ligand (OX40L) capable of binding OX40 Receptor (OX40R) and inhibiting OX40R-OX40L interaction. Such peptides, fusion proteins comprising them, as well as peptides and other molecules designed on their sequences, can be used as OX40R binding agents competing with natural OX40L for blocking OX40R-mediated cell signaling in the prophylaxis and/or treatment of diseases related to activated T cells.
    Type: Grant
    Filed: April 2, 2003
    Date of Patent: July 20, 2010
    Assignee: Merck Serono SA
    Inventors: Claudio Soto-Jara, Claudia Pena-Rossi
  • Publication number: 20100136628
    Abstract: The present invention discloses peptides isolated from the extracellular domain of OX40 Ligand (OX40L) capable of binding OX40 Receptor (OX40R) and inhibiting OX40R-OX40L interaction. Such peptides, fusion proteins comprising them, as well as peptides and other molecules designed on their sequences, can be used as OX40R binding agents competing with natural OX40L for blocking OX40R-mediated cell signaling in the prophylaxis and/or treatment of diseases related to activated T cells.
    Type: Application
    Filed: November 24, 2009
    Publication date: June 3, 2010
    Applicant: MERCK SERONO SA
    Inventors: CLAUDIO SOTO-JARA, CLAUDIA PENA-ROSSI
  • Publication number: 20090317380
    Abstract: The use of Apolipoprotein B, Apoliporpotein E, fragments and mimetics thereof is provided for diagnostic, detection, prognostic and therapeutic applications in prion diseases. More specifically, the invention provides the use of Apolipoprotein B or fragments thereof for modulating or identifying modulators of the prion protein replication which are implicated in the pathogenesis of transmissible spongiform encephalopathies and other prion diseases.
    Type: Application
    Filed: August 27, 2009
    Publication date: December 24, 2009
    Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
    Inventors: Claudio SOTO-JARA, Kinsey Maundrell
  • Patent number: 7598046
    Abstract: The use of Apolipoprotein B, Apolipoprotein E, fragments and mimetics thereof is provided for diagnostic, detection, prognostic and therapeutic applications In prion diseases. More specifically, the invention provides the use of Apolipoprotein B or fragments thereof for modulating or identifying modulators of the prion protein replication which are implicated in the pathogenesis of transmissible spongiform encephalopathics and other prion diseases.
    Type: Grant
    Filed: June 18, 2004
    Date of Patent: October 6, 2009
    Assignee: Laboratories Serono SA
    Inventors: Claudio Soto-Jara, Kinsey Maundrell
  • Publication number: 20080118938
    Abstract: A method is provided for the detection of misfolded proteins in a sample. These methods may be used to diagnose or indicate the potential for developing a disease associated with protein aggregation. In particular a method for serial automated cyclic amplification of a misfolded protein is disclosed.
    Type: Application
    Filed: September 6, 2007
    Publication date: May 22, 2008
    Inventors: Lisbell Estrada, Claudio Soto
  • Patent number: 7351526
    Abstract: A method for the diagnosis or detection of conformational diseases by assaying for a marker (the pathogenic conformer) of such diseases in a sample is described, which method comprises a cyclic amplification system to increase the levels of the pathogenic conformer which causes such diseases. In particular, such transmissible conformational diseases may be prion encephalopathies. Assays, diagnostic kits and apparatus based on such methods are also disclosed.
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: April 1, 2008
    Assignee: Laboratories Serono SA
    Inventors: Claudio Soto, Gabriella Saborio
  • Publication number: 20070155955
    Abstract: Short peptides and derivatives or analogs thereof for the treatment or prevention of IAAP related disorders, in particular amyloid deposits associated with Type I or Type II diabetes are herein described.
    Type: Application
    Filed: March 17, 2004
    Publication date: July 5, 2007
    Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
    Inventors: Youcef Fezoui, Claudio Soto-Jara